Remimazolam for Sedation in ICU Patients Undergoing Mechanical Ventilation
Status:
Not yet recruiting
Trial end date:
2024-06-30
Target enrollment:
Participant gender:
Summary
Sedation is a component of the care of critically ill patients who are undergoing mechanical
ventilation. Dexmedetomidine induces sedation while preserving a degree of arousability among
patients in the intensive care unit (ICU), and its use has resulted in a shorter time to
extubation, an increased number of days free from coma or delirium, a reduced incidence of
agitated delirium, prevention of delirium, and lower mortality than other agents administered
in certain populations. Hypotension and bradycardia are common side effects, which is lethal
for the patients with persistent or severe hemodynamic instability.
The pharmacological properties of rimazolom suggest that it is an ideal sedative drug for
critically ill patients, but there is no relevant clinical research to confirm it. Therefore,
this study mainly discusses the efficacy and safety of remidazolam in ICU patients with
mechanical ventilation, so as to provide theoretical basis for individualized sedation
treatment of patients with mechanical ventilation.